Anti-IgE antibodies such as omalizumab (also known as rhuMab-E25 or XolairTM) and Talizumab (also known as TNX-901) are currently approved by the U.S. Food and Drug Administration (FDA) for clinical use in patients with allergic asthma, food allergies, or other allergic conditions (Milgrom et al, 1999; Leung et al, 2003; Busse et al, 2011). Here, IGHE is linked to allergic asthma.